Everest Organics trades jubilantly on developing new API to treat Covid-19
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Everest Organics is currently trading at Rs. 327.50, up by 27.25 points or 9.08% from its previous closing of Rs. 300.25 on the BSE.
The scrip opened at Rs. 295.60 and has touched a high and low of Rs. 335.00 and Rs. 295.60 respectively. So far 47486 shares were traded on the counter.
The BSE group 'X' stock of face value Rs. 10 has touched a 52 week high of Rs. 469.95 on 26-May-2021 and a 52 week low of Rs. 199.70 on 13-Nov-2020.
Last one week high and low of the scrip stood at Rs. 335.00 and Rs. 295.60 respectively. The current market cap of the company is Rs. 262.00 crore.
The promoters holding in the company stood at 74.15%, while Institutions and Non-Institutions held 0.03% and 25.82% respectively.
Everest Organics has unveiled the successful development of an anti-viral API 'MOLNUPIRAVIR' an additional COVID -19 treatment drug that is being developed at Lab Scale for the first-line treatment of COVID-19 in adults patients with mild to moderate symptoms. Everest is planning and preparing to be an active player in viral segment in the upcoming future.
Everest Organics is a fast growing API and Bulk drug manufacturing company with world class facility and it is committed to manufacturing excellent quality products and customer service.
